Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Biogen Inc. (BIIB) — XLV Health Care · S&P 500 Profile |百健介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Biogen Inc. (BIIB) — Business, History & S&P 500 Profile |百健介紹

Biogen company profile · biotechnology (multiple sclerosis, Alzheimer's, rare diseases) · history · financial snapshot · S&P 500 rank #282 · 百健公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 30, 2026 (frozen benchmark)
Financials: FY2025 (ended Dec 31, 2025)
MARKET CAP
$37.49B
Oct 30, 2026 · Slickcharts (frozen benchmark)
S&P 500 WEIGHT
0.05%
Rank #282 · Oct 30, 2026 (Slickcharts)
FY2025 REVENUE
$9.89B
total revenue (+2.2% YoY)
FY2025 NET INCOME
$1.29B
FY2025 net income

SNAPSHOT

TickerBIIB (NASDAQ)
CompanyBiogen Inc.
GICS sector / industryHealth Care (XLV) / Biotechnology
S&P 500 rank (by weight)#282 · 0.05% (Oct 30, 2026)
Sector rank (by market cap)#35 in Health Care (Oct 30, 2026)
Share price (frozen benchmark)$253.62 (Oct 30, 2026)
HeadquartersCambridge, Massachusetts
Founded1978 (in Geneva, by Charles Weissmann and others; moved to Cambridge)
CEOChristopher A. Viehbacher (President and CEO)
Employeesabout 7,000 (2026 profile)
Market cap$37.49B (Oct 30, 2026)

WHAT IT DOES

Biogen is a biotechnology company focused on neuroscience: multiple sclerosis therapies (including Tysabri and Tecfidera), the Alzheimer's drug Leqembi (co-developed with Eisai), spinal muscular atrophy treatment Spinraza, and a pipeline in rare diseases and immunology. It also earns royalties and contract manufacturing revenue.

The model is patent-protected biologics: high prices on small patient populations fund long research cycles, and biosimilar competition erodes older franchises. FY2025 total revenue was $9.891B, up 2.2% from $9.676B, operating income was $1.86B (one data provider reports $1.88B on a different line basis — $1.86B is used here), net income was $1.293B, GAAP diluted EPS was $8.79 and non-GAAP diluted EPS was $15.28.

Leqembi is the swing factor: Alzheimer's uptake has been slower than hoped, and the drug's commercial trajectory decides whether the pipeline story holds.

BUSINESS SEGMENTS — FY2025

SegmentRevenueShareYoY
Multiple sclerosis———
Alzheimer's (Leqembi)———
Rare diseases and other———
Source: Biogen FY2025 results. Product-level revenues are not stated in the sources used; franchises are listed qualitatively with —.

HISTORY

YearMilestone
1978Founded in Geneva by Charles Weissmann and others as Biogen
1986First interferon product approved; the company moves to Cambridge, Massachusetts
1996Avonex approved for multiple sclerosis
2021Aduhelm approved for Alzheimer's, then commercially withdrawn
2025FY2025 total revenue reaches $9.891B, with net income of $1.293B; Leqembi rollout continues

COMPETITIVE POSITION

  • Neuroscience depth — decades of multiple sclerosis and neurology expertise.
  • Leqembi partnership — co-development with Eisai shares cost and risk.
  • Pipeline optionality — rare-disease and immunology programs diversify beyond neurology.
  • Competition — Roche, Novartis and biosimilars contest the same patients.
  • Pricing pressure — payers push back on biologic prices.

FINANCIAL SNAPSHOT — FY2025

Total revenue$9.891B (+2.2% YoY)
Operating income$1.86B
Net income$1.293B
GAAP diluted EPS / Non-GAAP diluted EPS$8.79 / $15.28
Source: Biogen FY2025 results (fiscal year ended Dec 31, 2025). Operating income basis note: $1.86B is used; one data provider reports $1.88B on a different line basis — the difference is noted, not smoothed. GAAP and non-GAAP EPS are stated separately, not mixed. Employee figure is a 2026 profile figure.

KEY RISKS

  • Leqembi uptake — slow Alzheimer's adoption would undercut the growth story.
  • Biosimilar erosion — older multiple sclerosis drugs lose share to biosimilars.
  • Pipeline failure — late-stage trial failures are the norm in neurology.
  • Pricing and reimbursement — payer negotiations cap biologic prices.
  • Aduhelm precedent — a prior Alzheimer's launch damaged credibility.

WHY IT MATTERS FOR THE S&P 500

Biogen is the S&P 500's neuroscience biotech: at a 0.05% index weight and #35 in Health Care by market cap, it is the index's main exposure to Alzheimer's and multiple sclerosis drug development.

Its Leqembi uptake and pipeline readouts are a standing read on neurology — Alzheimer's commercialization moves before broader biotech data does.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price — Oct 30, 2026 close) and Slickcharts S&P 500 analysis page (market cap)
FinancialsBiogen FY2025 results (fiscal year ended Dec 31, 2025), company profile sources
Sector classificationGICS (Biotechnology) via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

BIIB

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

代碼BIIB(NASDAQ)
公司Biogen Inc.
GICS 板塊/行業醫療保健(XLV)/生物科技
標普500排名(按權重)#282 · 0.05%(2026 年 10 月 30 日)
板塊內排名(按市值)醫療保健第 #35(2026 年 10 月 30 日)
股價(凍結基準)$253.62(2026 年 10 月 30 日)
總部美國麻省劍橋
成立1978 年(日內瓦,Charles Weissmann 等人創辦;後遷劍橋)
行政總裁Christopher A. Viehbacher(總裁兼行政總裁)
員工約 7,000(2026 年簡介)
市值$37.49B(2026 年 10 月 30 日)

業務概覽

百健是專注神經科學的生物科技公司:多發性硬化症療法(包括 Tysabri 與 Tecfidera)、阿爾茨海默病藥物 Leqembi(與衛材共同開發)、脊髓性肌萎縮症治療 Spinraza,以及罕見病與免疫學管線;另賺取專利費與合約生產收入。

其模式為專利保護的生物製劑:小患者群體的高定價資助漫長的研究週期,生物類似藥競爭侵蝕舊有特許經營。FY2025 總收入為 $9.891B,同比增長 2.2%(FY2024 為 $9.676B),營業利潤為 $1.86B(一家數據商按不同口徑報 $1.88B——本篇用 $1.86B),淨利潤為 $1.293B,GAAP 攤薄每股收益為 $8.79,非 GAAP 攤薄每股收益為 $15.28。

Leqembi 是波動因素:阿爾茨海默病用藥推廣慢於預期,其商業軌跡決定管線故事是否成立。

業務板塊 — FY2025

板塊收入佔比同比
多發性硬化症———
阿爾茨海默病(Leqembi)———
罕見病及其他———
來源:百健 FY2025 業績。所用來源未列各產品收入,故特許經營只作定性列示,記為 —。

歷史沿革

年份里程碑
1978在日內瓦創立,由 Charles Weissmann 等人創辦,名為 Biogen
1986首個干擾素產品獲批;公司遷往麻省劍橋
1996Avonex 獲批用於多發性硬化症
2021Aduhelm 獲批用於阿爾茨海默病,後商業撤回
2025FY2025 總收入達 $9.891B,淨利潤為 $1.293B;Leqembi 繼續推廣

競爭地位

  • 神經科學深度——數十年多發性硬化症與神經學專長。
  • Leqembi 夥伴關係——與衛材共同開發分攤成本與風險。
  • 管線選擇權——罕見病與免疫學項目分散於神經學之外。
  • 競爭——羅氏、諾華與生物類似藥爭奪同一批患者。
  • 定價壓力——付款方抵制生物製劑價格。

財務快照 — FY2025

總收入$9.891B(同比 +2.2%)
營業利潤$1.86B
淨利潤$1.293B
GAAP 攤薄每股收益/非 GAAP 攤薄每股收益$8.79/$15.28
來源:百健 FY2025 業績(財政年度截至 2025 年 12 月 31 日)。營業利潤口徑註:本篇用 $1.86B;一家數據商按不同口徑報 $1.88B——差異已註明,不作平滑。GAAP 與非 GAAP 每股收益分開列示,不相混淆。員工數字為 2026 年簡介數字。

主要風險

  • Leqembi 採用——阿爾茨海默病採用緩慢將削弱增長故事。
  • 生物類似藥侵蝕——舊有多發性硬化症藥物被生物類似藥奪取份額。
  • 管線失敗——後期試驗失敗在神經學屬常態。
  • 定價與報銷——付款方談判限制生物製劑價格。
  • Aduhelm 前例——先前的阿爾茨海默病上市損害信譽。

對標普500的重要性

百健是標普500的神經科學生物科技標的:指數權重 0.05%、醫療保健板塊市值第 #35,是指數對阿爾茨海默病與多發性硬化症藥物開發的主要敞口。

其 Leqembi 採用與管線結果,是神經學的常設讀數——阿爾茨海默病商業化往往先於更廣泛的生物科技數據變動。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格——2026 年 10 月 30 日收盤)及 Slickcharts 標普500分析頁(市值)
財務百健 FY2025 業績(財政年度截至 2025 年 12 月 31 日)、公司簡介來源
板塊分類GICS(生物科技),據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

BIIB

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · BIIB
Data as of Oct 30, 2026 · Financials FY2025 (10-K) · Market data Oct 2026
Previous · CBRE Group, Inc. (CBRE) — XLRE Real Estate · S&P 500 Profile |世邦魏理仕介紹Next · Crown Castle Inc. (CCI) — XLRE Real Estate · S&P 500 Profile |皇冠城堡介紹

Entered 2026-11-01 20:32 · updated 2026-11-14 23:02 · rev 5